Alexandria Real Estate Equities (ARE) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is cautiously negative — consensus has drifted lower since the Q1 print, occupancy is expected to fall further to ~86.6%, and the bar is low but not yet low enough to guarantee a beat given ongoing biotech demand headwinds and a still-elevated tenant watch list.

Bar: Consensus Core FFO of $1.63/share for Q2 2026 represents a sequential step-down from the $1.73 reported in Q1 2026 and a sharp ~30% decline year-over-year, reflecting the full weight of lease expirations, lower capitalized interest, and disposition dilution. The bar is low in absolute terms, but management's own guidance midpoint of ~$6.40 for the full year implies a back-half recovery that requires meaningful leasing progress — making any shortfall in occupancy or leasing volume particularly punishing. Guidance/Tone: Management's posture on the Q1 call was defensive but not panicked — they tightened the 4Q26 FFO range to $1.40–$1.50 (midpoint down $0.05), lowered year-end occupancy guidance by 150 bps to 87%, and widened the same-property NOI range to (10.5%)–(8.5%). The July 9 credit facility action (locking in a new $5B revolving credit facility at 0.725% margin, maturing January 2032) signals balance sheet confidence and is a modest positive heading into the print. Estimate Trajectory: Core FFO estimates for Q2 have drifted from $1.65 at the post-Q1 baseline to $1.63 today — a modest ~1.2% downward revision — while occupancy estimates have slipped from 87.3% to 86.6%, tracking below the guidance midpoint. Same-property NOI estimates have improved from (12.7%) to (10.9%), suggesting analysts are giving management some credit for the second-half recovery narrative. Stock Setup: ARE has rallied ~13% from the Q1 earnings close of $45.56 to ~$51.47 as of July 31, outperforming XLRE (+3.7%) and the S&P 500 (+4.5%) over the same period, driven almost entirely by multiple expansion (EV/EBITDA expanded from ~15.3x to ~16.5x) rather than estimate revisions. The stock trades at 0.57x book — near historic lows — suggesting value buyers have stepped in, but the multiple re-rating leaves less room for error. Wildcard: The single biggest swing factor is leasing volume and composition. Management guided for ~900,000 sq ft of Q2 leasing activity based on early pipeline signals — if public biotech demand remains near zero (as in Q1, which was unprecedented) and advanced technology tenants do not fill the gap, occupancy could undershoot the already-lowered guidance and force another guidance cut, which would likely reverse the recent stock recovery.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a low absolute bar on Core FFO ($1.63/share, down ~30% YoY), but occupancy is the bigger swing factor — at 86.6% consensus vs. 87.7% last quarter, any further deterioration risks a guidance cut and would likely pressure the stock more than an FFO miss.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data (Core FFO, Occupancy, Same-Property NOI Growth, Total Rental Revenue). Q1 2026 actuals and Q2 2025 actuals from Visible Alpha. Q2 2026 consensus as of August 2, 2026. FY 2026 guidance from ARE Q1 2026 Earnings Release (April 27, 2026) and Q1 2026 Earnings Call (April 28, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Core FFO per Share ($)

Occupancy Rate (%)

Pattern: Core FFO has been broadly in-line to slightly positive over the past several quarters, but occupancy has consistently missed or come in at the low end of expectations since Q1 2025, reflecting the structural demand headwinds in the life science leasing market. The Q1 2026 occupancy miss of 80 bps was the largest in recent history and sets a cautious tone heading into Q2.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management made meaningful downward revisions to occupancy and same-property NOI guidance on the Q1 2026 call (April 28), while holding the FY Core FFO midpoint flat. The July 9 credit facility action is the only post-earnings event and is a positive balance sheet signal, not an earnings revision.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Core FFO estimates for Q2 2026 have drifted modestly lower (~1.2%) since the post-Q1 baseline, while same-property NOI estimates have improved materially (from −12.7% to −10.9%), suggesting analysts are beginning to price in the second-half recovery narrative. Occupancy estimates have slipped below the guidance midpoint, which is the key risk to watch.

The most notable revision since the Q1 print is the improvement in same-property NOI estimates (from −12.7% to −10.9% for Q2, and from −12.8% to −10.6% for FY), suggesting analysts are giving management credit for the second-half recovery narrative driven by 1.1M sq ft of pre-leased space expected to deliver in September 2026. However, occupancy estimates have continued to drift lower, and the FY consensus of $6.36 sits slightly below the guidance midpoint of $6.40, indicating the street is not fully buying the recovery story yet.

Source: Visible Alpha Consensus and Actuals Data; ARE Q1 2026 Earnings Release and Earnings Call (April 27–28, 2026).

5. Stock Performance

Key Takeaway: ARE has rallied ~13% since the Q1 2026 earnings close, driven almost entirely by multiple expansion rather than estimate revisions — EV/EBITDA expanded from ~15.3x to ~16.5x. The stock has meaningfully outperformed both XLRE (+3.7%) and the S&P 500 (+4.5%) over the same period, suggesting value-oriented buyers have stepped in near 12-month lows, but the re-rating leaves the stock more vulnerable to a guidance cut.

ARE vs. XLRE (Real Estate Select Sector ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Close (April 27, 2026). Diamond marker indicates July 9, 2026 credit facility filing (8-K). Source: Stock Price Data (Yahoo Finance).

Valuation Context: ARE currently trades at 16.5x NTM EV/EBITDA (vs. ~15.3x at the Q1 earnings close), 0.57x Price/Book (near historic lows), and 7.7x Price/FCF. The 3-month rally of +27% has been driven almost entirely by multiple expansion (+7.8% in EV/EBITDA), not estimate revisions, which is a less durable driver. The 12-month return of −34% reflects the cumulative impact of occupancy declines, the historic dividend cut, and sector-wide life science headwinds.

Sector ETF: XLRE (Real Estate Select Sector SPDR Fund) is used as the sector benchmark. XLRE is a broad REIT ETF that includes diversified, industrial, and residential REITs alongside office/life science names, making it an imperfect but standard benchmark for ARE's sub-sector.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (NTM multiples as of July 31, 2026).

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the July 9 credit facility action — locking in a new $5B revolving credit facility at improved terms through January 2032 — which signals balance sheet confidence and reduces near-term refinancing risk heading into the print. No earnings-relevant operational announcements have been made since the Q1 call.

• July 9, 2026 — $5 Billion Credit Facility Terms Locked (8-K): ARE filed an 8-K disclosing it had entered into an escrow agreement to lock in terms for a Fourth Amended and Restated Credit Agreement providing a $5B unsecured senior revolving credit facility (plus $1B accordion option), maturing January 22, 2032 (with two 6-month extension options). The initial margin is 0.725% (vs. the existing facility). The facility replaces the existing Third Amended Credit Agreement (September 2024). Conditions to effectiveness must be satisfied by October 1, 2026. Implication: Positive — extends liquidity runway, reduces refinancing risk, and signals lender confidence in ARE's credit profile. Removes a potential overhang heading into the print. (Source: ARE 8-K, July 9, 2026)
• May 27, 2026 — Q2 2026 Earnings Call Scheduled: ARE announced its Q2 2026 results conference call for August 4, 2026. No operational update was provided. (Source: ARE Press Release, May 27, 2026)
• May 14, 2026 — Annual Meeting Results (8-K): Stockholders approved directors, executive compensation, and auditor at the annual meeting. No material changes to board composition or governance. (Source: ARE 8-K, May 14, 2026)
• April 27–28, 2026 — Q1 2026 Earnings (Last Earnings Event): Key operational updates: (1) Zero public biotech leases signed in Q1 — unprecedented in company history; (2) Occupancy fell 320 bps sequentially to 87.7% driven by 657K sq ft of key lease expirations; (3) Year-end 2026 occupancy guidance lowered 150 bps to 87.0% midpoint; (4) Same-property NOI guidance worsened 100 bps to (9.5%) midpoint; (5) 4Q26 FFO run-rate range tightened to $1.40–$1.50; (6) Tenant watch list grew to $25M–$30M; (7) Advanced technology tenants (defense, AI-adjacent) emerging as alternative demand source; (8) Disposition mix shifting toward JV structures for core assets. Implication: Sets a cautious baseline for Q2 — management guided for ~900K sq ft of Q2 leasing activity based on early pipeline signals, but this was explicitly not formal guidance.
• Macro / Sector: FDA Instability Remains a Headwind: Management described the FDA as a “major ongoing problem” with near-daily shock effects from leadership and staffing instability as of the Q1 call. FDA novel drug approvals are on pace with 2025 levels per Kilroy Realty (Q2 2026 call, July 28, 2026), which is a modest positive read-through, but the structural uncertainty around NIH funding and China competition remains a headwind for ARE’s public biotech tenant base.
• Macro / Sector: Life Science Capital Markets Improving: Biotech IPO and follow-on equity markets are open, and M&A/licensing activity is described as “exceptionally active” per Kilroy Realty (Q2 2026 call, July 28, 2026). The XBI (small-cap biotech index) is up more than 70% year-over-year per KRC. This is a positive leading indicator for future lab demand, though the lag between capital markets activity and physical leasing demand is typically 12–24 months.

7. Peer Commentaries & Read-Throughs

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for high-quality office/lab real estate, with Kilroy Realty (KRC) and Boston Properties (BXP) both reporting improving leasing demand, positive rent spreads, and strengthening capital markets — but both also flag that lab-specific demand remains the laggard vs. office, which is directly relevant to ARE’s core business.

Note on Scope: Only commentary from the last 60 days (on or after June 3, 2026) that addresses the current reporting quarter (Q2 2026) or forward outlook is included below. Q1 2025 earnings commentary from peers (which addressed prior-quarter results) is excluded. SL Green (SLG) and Kilroy Realty (KRC) both reported Q2 2026 results in late July 2026 and are the primary read-through sources.

7a. Kilroy Realty (KRC) — Q2 2026 Earnings Call (July 28, 2026)

Relevance to ARE: KRC is ARE’s closest peer in terms of geographic overlap (San Francisco, San Diego, Seattle) and tenant mix (life science + tech). KRC’s Q2 2026 commentary is the single most relevant read-through for ARE’s Q2 print.

• Life Science Demand Improving, But Still Lagging Office: KRC reported a “meaningful pickup in tours and proposal activity” at Oyster Point Phase 2 (South San Francisco), with tours increasing from 317K sq ft in Q1 2026 to over 800K sq ft in Q2 2026. The XBI is up more than 70% year-over-year. Biotech IPO and follow-on equity markets are open, and M&A/licensing is “exceptionally active.” FDA approvals are on pace with 2025 levels despite leadership/staffing transition. ARE Read-Through: Positive — the surge in South San Francisco tour activity is directly relevant to ARE’s Greater Boston and San Francisco Bay Area campuses. However, KRC noted that robotics companies are absorbing large blocks (100K+ sq ft) in the Peninsula, which may reduce available space for life science companies — a nuanced dynamic that could benefit ARE’s advanced technology tenant strategy.
• Leasing Volume Up 40%+ YoY; Positive Rent Spreads for First Time in ~2 Years: KRC executed ~376K sq ft of new and renewal leases in Q2 2026, bringing YTD volume to ~944K sq ft (+40% vs. H1 2025). GAAP rental rates were up 21% and cash rents up 6.1% on comparable leases. This marked the “first quarter that both GAAP and cash releases were positive in nearly two years.” Free rent was ~half a month per year of lease term, the most favorable in several years. ARE Read-Through: Cautiously positive — if KRC is seeing positive cash rent spreads for the first time in two years, ARE’s own leasing spread guidance of (15%)–(7%) cash basis may prove conservative. However, KRC’s portfolio skews more toward office than lab, and ARE’s specific lease expirations (including the Waltham Megacampus 232K sq ft expiration) may not benefit from the same dynamics.
• Tenant Urgency / FOMO Emerging in San Francisco: KRC described “definitely some degree of FOMO in the market” in San Francisco, with existing tenants demonstrating “greater sense of urgency” around early renewals. Active tenant demand in San Francisco has surpassed 10M sq ft — a level not seen since 2019. Only 20–25 high-quality large-block opportunities (100K+ sq ft) remain in the city for 25+ active tenants. ARE Read-Through: Positive for ARE’s San Francisco Bay Area Megacampus assets. Scarcity of large-block space in San Francisco could drive tenants toward ARE’s campus offerings, particularly for well-capitalized pharma and advanced technology users.
• Capital Markets for Office/Life Science Strengthening: KRC noted that deal volume nationally is up 20% year-over-year, with San Francisco being the biggest beneficiary. Buyers are “pricing risk more generously” for future leasing demand and CapEx requirements. KRC sold $348M year-to-date. ARE Read-Through: Positive for ARE’s $2.9B disposition program. Strengthening transaction markets support ARE’s ability to execute its capital recycling plan at reasonable cap rates.
• Guidance Affirmed; Same-Property NOI Growth of 25–125 bps: KRC affirmed its 2026 FFO guidance range of $3.49–$3.63/share and same-property NOI growth of 25–125 bps. Limitation: KRC’s same-property NOI is growing while ARE’s is declining ~10% — the two companies are at very different points in their occupancy cycles. KRC’s portfolio is also more office-weighted, so the lab-specific dynamics are less directly comparable.

7b. Boston Properties (BXP) — Q2 2026 Earnings Call (July 29, 2026)

Relevance to ARE: BXP has meaningful overlap with ARE in Greater Boston (including lab/life science assets via its Urban Edge portfolio) and New York. BXP’s commentary on lab demand and capital markets is a relevant secondary read-through.

• Lab Demand Remains Lackluster Despite Active Life Science Capital Markets: BXP explicitly noted “lackluster demand around the lab space market” in its Urban Edge portfolio, despite active biotech IPO and M&A markets. Capital raising for startup-stage companies (Series B/C/D) remains slow, impacting demand for proprietary lab space. BXP distinguished AI-driven office demand from the prior life science boom, noting AI companies lease “pure and simple office space” rather than expensive bespoke lab infrastructure. ARE Read-Through: Negative — BXP’s direct observation of lackluster lab demand in Boston is the most concerning read-through for ARE, which derives the majority of its revenue from purpose-built lab space in Greater Boston. This supports the risk that ARE’s Q2 leasing volume may disappoint, particularly for public biotech tenants.
• Occupancy Improving Strongly in Office; Lab Lagging: BXP’s in-service portfolio occupancy reached 88.4% as of June 30, 2026 (up 170 bps YTD), and the company now expects to end 2026 closer to 90% occupied. However, this improvement is driven by office leasing (AI, financial services, professional services), not lab. ARE Read-Through: Mixed — the broad office recovery is positive for sentiment, but ARE’s occupancy trajectory is driven by lab-specific demand, which BXP confirms is lagging.
• AI Demand Is Real But Not a Lab Story: BXP is leasing to AI companies in San Francisco, New York, Boston, and Seattle, but emphasizes these are office leases, not lab. BXP has consciously limited AI industry exposure to 1–2% of portfolio. ARE Read-Through: Relevant context for ARE’s advanced technology tenant strategy. ARE has been pursuing defense, AI-adjacent, and robotics tenants for certain development assets — BXP’s experience suggests this demand is real but may not require the specialized lab infrastructure that ARE’s assets provide, potentially limiting rental rates.
• FY 2026 FFO Guidance Raised by $0.05 to $6.99–$7.05/share: BXP raised its FY 2026 FFO guidance midpoint by $0.05, driven by stronger portfolio NOI, lower net interest expense, and higher fee income. Limitation: BXP’s guidance raise is driven by office leasing dynamics that are not directly applicable to ARE’s lab-focused portfolio. BXP’s same-property NOI is growing 1.8–2.6%, while ARE’s is declining ~10%.

7c. SL Green Realty (SLG) — Q2 2026 Earnings Call (July 23, 2026)

Relevance to ARE: SLG is a New York City office REIT with limited direct overlap with ARE’s life science portfolio. However, SLG’s commentary on capital markets, rent growth, and the broader office recovery provides useful macro context.

• NYC Office Market in Extraordinary Recovery: SLG described an “extraordinary and prolonged surge in business activity” in NYC, with economic occupancy up 300 bps in Q2 2026. Wall Street profits hit $21B in Q1 2026 (second-highest ever), and Q2 profits are up 50% year-over-year. NYC companies raised $21.1B in venture capital YTD (double 2025 levels). ARE Read-Through: Limited direct relevance — ARE’s New York presence is small relative to its core life science markets. However, the doubling of NYC venture capital funding is a positive leading indicator for biotech funding nationally.
• Significant FFO Guidance Raise of $1.20/share (+26%): SLG raised its FY 2026 FFO guidance by $1.20/share, driven by strong leasing, accelerated GAAP revenue recognition, and a large One Vanderbilt contribution. Limitation: SLG’s guidance raise is almost entirely NYC office-specific and driven by idiosyncratic factors (One Vanderbilt, early renewals) that have no read-through to ARE’s life science portfolio.
• Capital Markets: Trophy Office Spreads Tightening: CMBS originations are up ~30% year-over-year, and triple-A spreads on trophy office are now trading in line with or inside industrial/multifamily/self-storage. Manhattan investment sales volume jumped 50% in H1 2026. ARE Read-Through: Positive for ARE’s disposition program — tightening credit spreads and improving transaction volumes support ARE’s ability to execute its $2.9B disposition plan at reasonable cap rates.

Peer Read-Through Summary

Analysis: The cluster of open-market purchases by Executive Chairman Joel Marcus (25,000 shares, ~$1.04M total) over three consecutive days immediately following the Q1 2026 earnings release is a meaningful bullish signal. Marcus is the company’s founder and has deep knowledge of the business — his willingness to buy aggressively at prices near 12-month lows ($40–$44 range) suggests he views the stock as materially undervalued relative to intrinsic value. The EVP-CTO also purchased 3,500 shares on the Q1 earnings close date. The CFO’s June sale was a pre-planned 10b5-1 transaction and should not be interpreted as a negative signal.

Source: Insider Transaction Data (SEC Form 4 Filings).